About REXAHN

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing the next generation of targeted therapeutics for the treatment of cancer.
Rexahn's clinical development programs target specific proteins that are selectively localized in human cancer cells and not in healthy tissues resulting in increased efficacy and reduced toxicity.


News

Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update


Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin™ in Patients with Metastatic Triple Negative Breast Cancer


More


Portfolio